Page last updated: 2024-12-10
10-deoxymethynolide
Description
10-Deoxymethynolide is a **macrolide antibiotic** produced by the bacterium *Streptomyces sp.* It is a **potent inhibitor of bacterial protein synthesis**, specifically targeting the **elongation factor G (EF-G)**.
Here's why 10-deoxymethynolide is important for research:
**1. Antibacterial Activity:**
* Its potent inhibition of EF-G makes it a promising candidate for the development of new antibiotics against **multidrug-resistant (MDR) bacteria**.
* It shows activity against a broad spectrum of bacteria, including **Gram-positive**, **Gram-negative**, and **anaerobic** strains.
**2. Unique Mechanism of Action:**
* 10-Deoxymethynolide binds to EF-G differently than other macrolides, suggesting a **novel mechanism of action**. This is important because it could help circumvent resistance mechanisms that target other macrolides.
**3. Structural Insights:**
* The molecule's unique structure allows for structural studies to better understand the **interaction between EF-G and antibiotics**. This information can be used to design more effective and specific antibiotics.
**4. Lead Compound for Drug Development:**
* 10-Deoxymethynolide serves as a **lead compound** for the development of new antibiotics. Researchers are exploring its potential for clinical use by modifying its structure to improve its pharmacological properties.
**5. Tool for Studying Bacterial Protein Synthesis:**
* It can be used as a **tool to study the mechanism of bacterial protein synthesis** and to identify potential targets for new antibiotics.
**Overall, 10-deoxymethynolide is a promising molecule with significant potential for the development of new antibiotics and the advancement of our understanding of bacterial protein synthesis.**
10-deoxymethynolide: structure given in first source; parent aglycone of methymycin and neomethymycin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
10-deoxymethynolide : A macrolide that consists of oxacyclododec-9-ene-2,8-dione bearing four methyl substituents at positions 3, 5, 7 and 11 as well as a hydroxy group at position 4 and an ethyl substituent at position 12. The aglycone of the macrolide antibiotic 10-deoxymethymycin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 5282031 |
CHEBI ID | 29461 |
SCHEMBL ID | 2880039 |
MeSH ID | M0212720 |
Synonyms (10)
Synonym |
(3r,4s,5s,7r,9e,11r,12r)-12-ethyl-4-hydroxy-3,5,7,11-tetramethyloxacyclododec-9-ene-2,8-dione |
81644-19-1 |
10-deoxymethynolide |
LMPK04000034 |
DB07703 |
(3r,4s,5s,7r,9e,11r,12r)-12-ethyl-4-hydroxy-3,5,7,11-tetramethyl-1-oxacyclododec-9-ene-2,8-dione |
CHEBI:29461 |
SCHEMBL2880039 |
Q27096921 |
DTXSID801037179 |
Roles (1)
Role | Description |
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
macrolide | A macrocyclic lactone with a ring of twelve or more members derived from a polyketide. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 8 (80.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.07
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.07 (24.57) | Research Supply Index | 2.40 (2.92) | Research Growth Index | 4.46 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |